A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Hoffmann-La Roche
Nuvectis Pharma, Inc.
Eli Lilly and Company
AstraZeneca
Maia Biotechnology
Plexium, Inc.
Maia Biotechnology
EMD Serono
Delfi Diagnostics Inc.
Mayo Clinic
Rondo Therapeutics
Bristol-Myers Squibb
Immuneering Corporation
Novartis
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
Immuneering Corporation
University of Birmingham
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Carisma Therapeutics Inc
Nimbus Therapeutics
Merck Sharp & Dohme LLC
Pfizer
Advaxis, Inc.
Icahn School of Medicine at Mount Sinai
AO GENERIUM
Mural Oncology, Inc
Adaptimmune
Hangzhou Normal University
H. Lee Moffitt Cancer Center and Research Institute
Blueprint Medicines Corporation
Novartis
Checkpoint Therapeutics, Inc.
University of Cologne
Novartis
Elevation Oncology
Takeda
Chonnam National University Hospital
Endocyte
Endocyte
KitovPharma
Acrotech Biopharma Inc.
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Rochester
M.D. Anderson Cancer Center